ABSTRACT
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a kind of rare and highly invasive hematological malignancy. Because of its low incidence, there is still no consensus on its standard treatment. For young patients, high intensity chemotherapy combined with hematopoietic stem cell transplantation is often used. Elderly patients who cannot accept hematopoietic stem cell transplantation receive low intensity chemotherapy. In December 2018, tagraxofusp, a new targeted drug, was approved by the U. S. Food and Drug Administration specially for treatment-naive and previously-treated BPDCN patients (age≥2 years old). Some targeted drugs, such as venetoclax and daratumumab, have certain effects on the treatment of BPDCN. The efficacies of PD-1/PDL-1 inhibitors and anti CD123 chimeric antigen receptor T cell immunotherapy need further researches.
ABSTRACT
Blastic plasmacytoid dendritic cell neoplasm (BPDCN)is a kind of rare and highly invasive hematological malignancy. Because of its low incidence,there is still no consensus on its standard treatment. For young patients,high intensity chemotherapy combined with hematopoietic stem cell transplantation is often used. Elderly patients who cannot accept hematopoietic stem cell transplantation receive low intensity chemo-therapy. In December 2018,tagraxofusp,a new targeted drug,was approved by the U. S. Food and Drug Administration specially for treatment-naive and previously-treated BPDCN patients (age≥2 years old). Some targeted drugs,such as venetoclax and daratumumab,have certain effects on the treatment of BPDCN. The efficacies of PD-1 / PDL-1 inhibitors and anti CD123 chimeric antigen receptor T cell immunotherapy need further researches.